Prothena (PRTA) has promising candidates for Alzheimer's disease in its pipeline. The successful development of the candidates will be a big boost for the company.
Here are three highly profitable stocks that Wall Street thinks will soar 39% or more within the next 12 months. The consensus price target for Bristol Myers Squibb (NYSE: BMY) is 39% above the big drugmaker's current share price. This forward earnings multiple is well below the average forward price-to-earnings ratio of 13.4 for pharmaceutical stocks in the S&P 500.
Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.